Feature | SCAI | May 21, 2020

SCAI Announces 2020 Late-breaking Clinical Studies

SCAI Announces 2020 Late-breaking Clinical Studies, featured clinical research sessions. #SCAI2020

May 21, 2020 — Here is the list of late-breaking study presentations and links to articles about each of them from the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions Virtual Conference, which toiok place May 14-16. Sessions share the latest advances in interventional cardiology and featured late-breaking clinical research. Find the entire virtual meeting program and links to the archived on-demand sessions at www.scai.org/scai2020.

Featured Interventional Cardiology Clinical Research
Thursday, May 14, 2020 2:50-4:40 pm EDT

   • A Telemedicine-Based STEMI Network that Encompasses 100 Million Patients – Latin America Telemedicine Infarct Network (LATIN) and Public Good, presented by Sameer Mehta, M.D.

  • Safety and Efficacy of the Synergy Biodegradable-Polymer Everolimus-Eluting Stent vs. Durable-Polymer Drug-Eluting Stents in High-Risk Patients Undergoing PCI: Insights From the TWILIGHT Trial, presented by Usman Baber, M.D

   • Reduction of Revascularization in Patients with Hypertriglyceridemia With Icosapent Ethyl: Insights From REDUCE-IT REVASC, presented by Benjamin E. Peterson, M.D.

   • Autologous CD34 Cell Therapy for Treatment of Coronary Microvascular Dysfunction in Patients With Angina and Non-Obstructive Coronary Arteries, presented by Timothy D. Henry, M.D.

   • Outcomes with Intermediate Left Main Disease on Coronary CT Angiography in the ISCHEMIA Trial (ISCHEMIA Intermediate LM Substudy), presented by Sripal Bangalore, M.D.

   • Optical Coherence Tomography (OCT) Measures Predicting Fractional Flow Reserve (FFR): The OMEF Study, presented by Rocco Vergallo, M.D.

   • Strict Versus No Fasting Prior to Cardiac Catheterization: A Prospective Evaluation of Safety and Clinical Outcomes: Can We Safely Have Our Patients Eat With Cardiac Catheterization – Nix or Allow: The CHOW NOW Study, presented by Abhishek Mishra, M.D.
 

Congenital Heart Disease Late-Breaking Science
Friday, May 15, 2020 1:30-2:25 pm EDT

   • Primary Outcomes of the Harmony Transcatheter Pulmonary Valve Pivotal Trial, presented by John P. Cheatham, M.

   • The Melody Transcatheter Pulmonary Valve: 10-Year Outcomes in the Original U.S. Investigational Device Exemption Trial Cohort, presented by Thomas K. Jones, M.D.

   • One-Year Results From the COMPASSION S3 Trial: Treatment of Patients With a Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduit or Previously Implanted Pulmonic Valve With the Sapien 3 Transcatheter Heart Valve, presented by Vasilis C. Babaliaros, M.D.

 

Other SCAI 2020 News:

How Cardiology Dealt With the COVID-19 Surge in New York City — Columbia Medical Center's efforts explained by Ajay Kirtane, M.D.

Cindy Grines Becomes SCAI President

 

 
For more information or to view the full program: www.scai.org/scai2020

 
#SCAI2020


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now